Cargando…
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
BACKGROUND: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595051/ https://www.ncbi.nlm.nih.gov/pubmed/26438237 http://dx.doi.org/10.1186/s12885-015-1663-5 |
_version_ | 1782393525657141248 |
---|---|
author | de Groot, Stefanie Vreeswijk, Maaike PG Welters, Marij JP Gravesteijn, Gido Boei, Jan JWA Jochems, Anouk Houtsma, Daniel Putter, Hein van der Hoeven, Jacobus JM Nortier, Johan WR Pijl, Hanno Kroep, Judith R |
author_facet | de Groot, Stefanie Vreeswijk, Maaike PG Welters, Marij JP Gravesteijn, Gido Boei, Jan JWA Jochems, Anouk Houtsma, Daniel Putter, Hein van der Hoeven, Jacobus JM Nortier, Johan WR Pijl, Hanno Kroep, Judith R |
author_sort | de Groot, Stefanie |
collection | PubMed |
description | BACKGROUND: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). METHODS: Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. RESULTS: Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. CONCLUSIONS: STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01304251, March 2011 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1663-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4595051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45950512015-10-07 The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study de Groot, Stefanie Vreeswijk, Maaike PG Welters, Marij JP Gravesteijn, Gido Boei, Jan JWA Jochems, Anouk Houtsma, Daniel Putter, Hein van der Hoeven, Jacobus JM Nortier, Johan WR Pijl, Hanno Kroep, Judith R BMC Cancer Research Article BACKGROUND: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). METHODS: Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. RESULTS: Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. CONCLUSIONS: STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01304251, March 2011 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1663-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-05 /pmc/articles/PMC4595051/ /pubmed/26438237 http://dx.doi.org/10.1186/s12885-015-1663-5 Text en © de Groot et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article de Groot, Stefanie Vreeswijk, Maaike PG Welters, Marij JP Gravesteijn, Gido Boei, Jan JWA Jochems, Anouk Houtsma, Daniel Putter, Hein van der Hoeven, Jacobus JM Nortier, Johan WR Pijl, Hanno Kroep, Judith R The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study |
title | The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study |
title_full | The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study |
title_fullStr | The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study |
title_full_unstemmed | The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study |
title_short | The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study |
title_sort | effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in her2-negative breast cancer patients: a randomized pilot study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595051/ https://www.ncbi.nlm.nih.gov/pubmed/26438237 http://dx.doi.org/10.1186/s12885-015-1663-5 |
work_keys_str_mv | AT degrootstefanie theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT vreeswijkmaaikepg theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT weltersmarijjp theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT gravesteijngido theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT boeijanjwa theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT jochemsanouk theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT houtsmadaniel theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT putterhein theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT vanderhoevenjacobusjm theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT nortierjohanwr theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT pijlhanno theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT kroepjudithr theeffectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT degrootstefanie effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT vreeswijkmaaikepg effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT weltersmarijjp effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT gravesteijngido effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT boeijanjwa effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT jochemsanouk effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT houtsmadaniel effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT putterhein effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT vanderhoevenjacobusjm effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT nortierjohanwr effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT pijlhanno effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy AT kroepjudithr effectsofshorttermfastingontolerancetoneoadjuvantchemotherapyinher2negativebreastcancerpatientsarandomizedpilotstudy |